Lung Cancer Screening Market Report 2025

The lung cancer screening market size has grown strongly in recent years. It will grow from $3.03 billion in 2024 to $3.33 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth during the historic period can be attributed to the rising prevalence of tobacco use, increasing awareness of early cancer detection, expansion of government initiatives and screening programs, a growing geriatric population, and greater penetration of private diagnostic centers.

The lung cancer screening market size is expected to see strong growth in the next few years. It will grow to $4.79 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth during the forecast period can be attributed to the increasing burden of air pollution and occupational exposures, rising clinical evidence supporting the benefits of early screening, expanding availability of insurance coverage, growing urbanization and lifestyle changes, and rising investments in radiology infrastructure. Key trends in this period include the integration of cloud-based imaging platforms, advancements in radiomics and image analytics, development of portable and point-of-care imaging devices, incorporation of decision support systems into radiology workflows, and progress in non-invasive biomarker-based screening.

The rising smoking rates are expected to drive growth in the lung cancer screening market. Smoking, the inhalation of smoke from burning substances, primarily tobacco has been increasing due to rising stress levels, with more individuals turning to smoking as a coping mechanism. Lung cancer screening helps address this trend by enabling early detection of smoking-related health risks, encouraging smoking cessation, and supporting public health initiatives to reduce tobacco use. For example, according to the Office for National Statistics in September 2023, around 4.5 million adults in Great Britain, or 8.7% of the population, reported using e-cigarettes either daily or occasionally in 2022, up from 7.7% in 2021. Therefore, the growing prevalence of smoking is fueling the lung cancer screening market.

Key players in the lung cancer screening market are focusing on innovations in artificial intelligence (AI) to improve early detection and diagnostic precision in chest imaging. Technologies such as normal flagging enhance diagnostic accuracy, reduce false positives, and help prioritize cases that require further review by automatically identifying scans with no abnormal findings. In May 2025, Lunit Inc., a South Korea-based medtech company, launched INSIGHT CXR4, its next-generation AI-powered chest X-ray analysis solution, now CE MDR-certified for use across Europe. This system assists radiologists by detecting 12 chest abnormalities including lung nodules, pneumonia, and acute bone fractures and incorporates features such as current-prior image comparison to support early disease detection and clinical decision-making.

In August 2022, Intelerad Medical Systems Inc., a U.S.-based medical imaging software provider, acquired PenRad Technologies, Inc. for an undisclosed sum. Through this acquisition, Intelerad aims to expand its offerings in mammography and lung cancer screening, improving workflow efficiency for radiologists and enhancing patient outcomes. PenRad Technologies Inc. specializes in lung cancer screening software, strengthening Intelerad’s capabilities in advanced imaging solutions.

Major players in the lung cancer screening market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AstraZeneca Plc, Abbott Laboratories Inc., Canon Inc., Medtronic Plc, Siemens Healthineers AG, Koninklijke Philips N.V., GE Healthcare Technologies Inc., Quest Diagnostics Incorporated, Agilent Technologies Inc., Shimadzu Corporation, NeoGenomics Laboratories Inc., Freenome Holdings Inc., Biodesix Inc., Lunit Inc., Infervision, Riverain Technologies, VisionGate, and Delfi Diagnostics Inc.

North America was the largest region in the lung cancer screening market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lung cancer screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lung cancer screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Lung cancer screening is a preventive strategy aimed at detecting cancer in the lungs at an early stage, often before any noticeable symptoms appear. It targets individuals at higher risk due to specific health or lifestyle factors. The goal of this process is to identify abnormal changes or growths in lung tissue early, improving the chances of effective treatment and reducing the overall impact of the disease.

The primary diagnostic methods for lung cancer screening include low-dose spiral computed tomography (CT) scans and chest X-rays. Low-dose spiral CT scans use reduced radiation to produce detailed cross-sectional images of the lungs, allowing early detection of lung abnormalities with high sensitivity. These scans are applied for different lung cancer types, including non-small cell lung cancer and small cell lung cancer, and across various age groups, such as individuals aged 50 and older or below 50. They are utilized by multiple end users, including hospitals, clinics, diagnostic centers, and others.

The lung cancer screening market research report is one of a series of new reports that provides lung cancer screening market statistics, including the lung cancer screening industry global market size, regional shares, competitors with the lung cancer screening market share, detailed lung cancer screening market segments, market trends, and opportunities, and any further data you may need to thrive in the lung cancer screening industry. This lung cancer screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lung cancer screening market includes revenues earned by entities by providing services such as radiology interpretation, diagnostic follow-up procedures, patient risk assessment, and telehealth consultation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.